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On January 20, 2015, President Barack Obama ann-
ounced a major research initiative, “Tonight, I am 
launching a new personalized medicine initiative to 
bring us closer to curing diseases like cancer and dia-
betes and to give all of us access to the personalized 
information we need to keep ourselves and our fami-
lies healthier”.[1] The announcement itself indicates 
commitment and high expectations. Indeed personal-
ized or precision medicine (PM) is presently consid-
ered to represent one of the most important trends in 
medicine. It may be regarded as another milestone in 
the ‘evolution’ of medicine beginning from the theory 
of ancient humoralism. This dominated medicine and 
science over a period or several thousands of years 
until the mid-nineteenth century when it was replaced 
by the introduction of modern cellular pathology. 
Further essential milestones on the way to PM are the 
discovery of the DNA by Watson and Crick in 1953 
and the Human Genome Project determining to se-
quence the DNA that was completed in 2003[2]. 
Precision medicine represents an approach for the 
prevention and treatment of diseases that take indi-
vidual biological variability into account. There is no 
formal uniform standardized definition for ‘personal-
ized’ or ‘precision’ medicine (Table 1). We prefer the 
definition by the European Union ‘providing the right 
treatment to the right patient, at the right dose at the 
right time’[3]. The general idea of PM is not new; for 
example blood typing has been used to guide blood 
transfusions for more than a century. The prospect of  
Table 1. Attempts to define personalized medicine (adapted 
after Landeck et al. 2015[5]) 
European Union 
Providing the right treatment to the right patient, at the right dose at 
the right time. 
Personalized Medicine Coalition 
The use of new methods of molecular analysis to better manage a 
patient’s disease or predisposition to disease. 
President’s Council of Advisors on Science and Technology 
The tailoring of medical treatment to the individual characteristics of 
each patient. 
American Medical Association 
Health care that is informed by each person’s unique clinical, genetic, 
and environmental information. 
National Institute of Health 
A form of medicine that uses information about a person’s genes, 
proteins, and environment to prevent, diagnose, and treat disease. 
 
applying this concept broadly, however, has been con-
siderably enhanced by recent developments such as 
the establishment of large-scale biologic databases 
(e.g. the human genome sequence), powerful tech-
nologies and methods for patient characterization such 
as genomics, proteomics, metabolomics, and compu-
tational tools for analysing ‘big data’[1]. 
Disease diagnosis and monitoring based on physio-
logical and morphological characteristics are vener-
able established practices. More recently the term 
‘biomarker’ evolved in connection with the increasing 
interaction between molecular biology research and 
medicine. A biomarker is ‘a characteristic that is ob-
jectively measured and evaluated as an indicator of 
normal biological and pathogenic processes, or phar-
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macologic responses to a therapeutic intervention’[4]. 
Markers can be sub-grouped into diagnostic- and 
drug-response markers. Many more types can be de-
fined by their specific application. Table 2 gives a 
summary on the different purposes of modern bio-
markers related to pharmacotherapy[5].  
At present, there are approximately 50 drugs app-
roved in the EU[5] with a recommended or mandatory 
required biomarker determination either for efficacy 
or side effect prediction, and considerably more than 
137 in the USA as of November 2015[6]. It can be as-
sumed that many more are coming. This means that 
the majority of therapeutic products of the future will 
come as a double pack: a diagnostic test and a drug.  
In the past, clinical biomarker analyses were typ-
ically performed in local labs and sometimes under 
relatively uncontrolled conditions. With the increasing 
use of biomarkers in the daily routine, health autho-
rities such as the European Medicines Agency and the 
FDA are establishing better standards to regulate how 
to qualify and validate a new biomarker and the re-
spective pre-analytical and analytical technologies 
used to assay the marker. This is in particular chal-
lenging for companion diagnostic biomarkers. Com-
panion diagnostics are co-developed with a particular 
drug and their application is often listed as mandatory 
in the drug label. Thus, the regulatory aspects of such 
diagnostic development are of high and increasing 
relevance in the next future. 
Advances in Precision Medicine (APM) would like 
to provide a vital forum and fruitful platform for the 
exchange of important information in all areas of the 
growing field of precision medicine and biomarker 
research, development and application in the broadest 
senses. It will follow an indication agnostic approach.  
The target audiences of APM are the scientific and 
healthcare communities of basic scientists and clini-
cians from academia, regulatory institutions, and 
industry. This includes pharma, diagnostic and de-
vice companies.  
We appreciate articles on all stages in biomarker 
discovery (research and development) as well as bio-
marker utilization, i.e. identification, validation and 
application. Additional to biomarkers and their assays, 
novel technologies, new strategies and general de-
velopments which may have application in the field 
of PM are welcome. This may apply for new appro-
aches for marker, assay and device development stra-
tegies, collaborative approaches (e.g. industry, aca-
demic and governmental) and regulatory matters with 
impact on personalized medicine.  
Innovative therapies, even if not guided by bio-
markers, may be considered if they specifically target 
a particular molecule or a special patient subpopulation. 
Validation studies are highly encouraged. There is 
a considerable discrepancy between the number of 
biomarkers identified and reported in the literature 
(~150,000) and the very few (~100) actually used in 
the daily practice[7]. It seems that there may be a major 
issue with regard to the reproducibility of published  
 
Table 2. Biomarker types based on intended use (adapted after Landeck et al. 2015[5]) 
Purpose Type Definition Example 
Stratification and 
patient selection 
Predictive efficacy BM that categorizes patients by likelihood of response 
to a particular treatment, enabling enrichment of 
patients most likely to respond to therapy 
Human epidermal growth factor receptor 
2 (HER2) status for treatment with 
trastuzumab (Herceptin®) 
Predictive safety BM that predicts whether a patient develops an adverse 
reaction to a prescribed drug, enabling enrichment of 
patients that can be safely treated with a specific drug  
UGT1A1 mutation leading to increased 
toxicity of Irinotecan therapy (oncology) 
Prognostic BM that categorizes patients by degree of risk for 
disease occurrence or progression in the absence of a 
therapeutic intervention 
Oncotype Dx® or Mammaprint Dx® for 
prognosis of breast cancer 
Drug response and 
measurement 
Pharmaco-dynamic BM showing that a biological response has occurred in 
a patient who has received a therapeutic intervention 
and for which the magnitude of change is linked to the 
response, depiction of target engagement 
phosphorylated substrates of Bcr-Abl, 
c-Met, MEK kinases (oncology) 
Safety and toxicologic 
monitoring 
BM used to detect or monitor adverse effects in  
patients receiving a therapeutic intervention 
urine levels of kidney injury molecule 1 
for renal toxicity, 
serum levels of alanine aminotransferase  
for liver toxicity 
Surrogate, response Subsets of BM that are intended to serve as a substitute 
for a clinically meaningful endpoint, lab measurements 
correlate with patients' health status or survival 
mean tumor volume as surrogate marker 
for progression-free or overall survival, 
HbA1c and blood glucose as surrogates 
for diabetes care 
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reports across laboratories and in particular across 
populations[8]. Thus there is a need for more tran-
sparency and major cooperative efforts for adequate 
biomarker validation. APM will therefore support 
publishing of negative data. Finally, the successful 
biomarker development frequently requires the joint 
efforts of several, often quite diverse partners[9,10]. 
Therefore we appreciate manuscripts on describing 
and encouraging such collaborations.  
Articles include original articles, reviews, perspectives, 
editorials, commentaries, position papers, conference 
reports and letters to the editor. The journal welcomes 
unsolicited article proposals in all categories except 
for “Editorials”. Authors are encouraged to refer to 
APM’s “Section Policies” at www.apm@whioce.com 
for more information. 
We are very pleased to have recruited outstanding 
experts and pioneers in the field for our outstanding 
editorial board (please see the team at 
www.apm@whioce.com). This includes opinion leaders 
from academia and industry from all over the world.  
We would like to thank WHIOCE Publishing Pte 
Ltd, Singapore (www.whioce.com) enabling us to es-
tablish this journal. We very much appreciate their 
generous support. Together we are devoted to making 
APM a high-quality, frequently cited journal that pub-
lishes superior scholarly articles and disseminates the 
latest advances in the field. To ensure high quality, the 
articles will be peer-reviewed. To achieve a broad 
reach it will be an open access journal, with moderate 
publication fees. Initially we will start with biannual 
publications, however, if there is demand we will cer-
tainly consider quarterly publications subsequently.  
Finally, we would like to invite you to read our 
journal and to submit your most interesting work to us. 
Although we will publish original scientific work 
from the outset, we will provide in particular space for 
high quality reviews and perspective articles. Please 
feel encouraged to contact us to propose the submis-
sion of good quality papers. We are looking forward to 
becoming a vivid journal dedicated to one of the most 
dynamic, interdisciplinary and potentially even revo-
lutionary fields of medicine. 
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